I-MAB

I-Mab a clinical stage biopharmaceutical company discovers develops and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa a long-acting growth hormone which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210 a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab a CD73 antibody which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai the People's Republic of China.